Trial fails of ruxolitinib in COVID-19 – Novartis

Trial fails of ruxolitinib in COVID-19 – Novartis

ZURICH — Novartis said a late-stage clinical trial of ruxolitinib on top of standard therapy showed no significant reduction in severe complications of COVID-19, including death, respiratory failure requiring mechanical ventilation or admission to the intensive care unit. The trial also did not show relevant benefit for other endpoints including mortality rate by day 29 […]
Read More


LME base metals rise on vaccine euphoria, U.S. stimulus hopes

Previous article

Germany likely to avert second recession despite new lockdown – minister

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Business